Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,932 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Conditions
Alzheimer Disease
Interventions
Anatabloc(R), Placebo
Dietary Supplement
Lead sponsor
Rock Creek Pharmaceuticals, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Sarasota, Florida
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Recruiting Not applicable Interventional

Adapting RDAD for DS

NCT07425769
Conditions
Down Syndrome (DS), Alzheimer's Disease (AD)
Interventions
Remote Exercise Sessions, Caregiver Education Sessions
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Kansas
Recruiting No phase listed Observational Accepts healthy volunteers

ADRC Clinical Cohort (Alzheimer's Disease)

NCT06703541
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
25 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Conditions
Alzheimers Disease
Interventions
[F18] T808
Radiation
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Conditions
Alzheimer's Disease
Interventions
Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, Placebo capsules, Placebo wafers
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tucson, Arizona • Irvine, California • La Jolla, California + 10 more
Conditions
Alzheimer's Disease
Interventions
ST101, Placebo
Drug
Lead sponsor
Sonexa Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Costa Mesa, California • Redlands, California • San Diego, California + 12 more
Conditions
Alzheimer Disease
Interventions
Simufilam 100 mg oral tablet, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Surprise, Arizona • Imperial, California + 12 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

Senicapoc in Alzheimer's Disease

NCT04804241
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Senicapoc, Placebo Tablet
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
55 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Sacramento, California • Walnut Creek, California
Conditions
Alzheimer Disease
Interventions
Gantenerumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Down Syndrome, Alzheimer Disease, Obesity
Interventions
Diet, Health Education
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Irvine, California • Sacramento, California + 29 more
Conditions
Alzheimers Disease
Interventions
[123I] AV 39
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer Disease
Interventions
Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more
Conditions
Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
Interventions
11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Conversations as a Means to Delay the Onset of Alzheimer's Disease

NCT01571427
Conditions
Mild Cognitive Impairment, Cognitive Change
Interventions
Active social engagement group, Control group
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
70 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Dementia, Cognitive Impairment, Alzheimer Disease
Interventions
IADLSys system
Diagnostic Test
Lead sponsor
Bijan Najafi, PhD
Other
Eligibility
50 Years to 95 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Not listed No phase listed Observational Accepts healthy volunteers

Longitudinal Innate Immunity and Aging Study

NCT03944603
Conditions
Healthy Older Adults Ages 60-89
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Recruiting No phase listed Observational Accepts healthy volunteers

Dominantly Inherited Alzheimer Network (DIAN)

NCT00869817
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2031
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more